Let’s start up with the current stock price of Cancer Genetics Inc. (CGIX), which is $5.73 to be very precise. The Stock rose vividly during the last session to $6.40 after opening rate of $6.39 while the lowest price it went was recorded $5.61 before closing at $6.55.
Recently in News on February 16, 2021, Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules. Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced the closing of its previously announced registered direct offering with several healthcare-focused institutional investors of 2,777,778 shares of its common stock at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $17.5 million, before deducting placement agent fees and offering expenses. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Cancer Genetics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $17.50 on 02/10/21, with the lowest value was $2.78 for the same time period, recorded on 01/04/21.
Cancer Genetics Inc. (CGIX) full year performance was 35.78%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Cancer Genetics Inc. shares are logging -67.26% during the 52-week period from high price, and 198.44% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.92 and $17.50.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1919543 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Cancer Genetics Inc. (CGIX) recorded performance in the market was 106.86%, having the revenues showcasing 159.28% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 24.58M, as it employees total of 110 workers.
The Analysts eye on Cancer Genetics Inc. (CGIX)
During the last month, 0 analysts gave the Cancer Genetics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 3.47, with a change in the price was noted +2.00. In a similar fashion, Cancer Genetics Inc. posted a movement of +53.62% for the period of last 100 days, recording 1,335,394 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CGIX is recording 0.04 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.02.
Technical rundown of Cancer Genetics Inc. (CGIX)
Raw Stochastic average of Cancer Genetics Inc. in the period of last 50 days is set at 21.90%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 15.99%. In the last 20 days, the company’s Stochastic %K was 22.33% and its Stochastic %D was recorded 24.66%.
Considering, the past performance of Cancer Genetics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 106.86%. Additionally, trading for the stock in the period of the last six months notably improved by 88.49%, alongside a boost of 35.78% for the period of the last 12 months. The shares increased approximately by -33.37% in the 7-day charts and went down by 71.04% in the period of the last 30 days. Common stock shares were driven by 159.28% during last recorded quarter.